INITIATIVES THAT IMPACT PRICING AND REIMBURSEMENT OF ORPHAN (AND ULTRA ORPHAN) DRUGS: REVIEW OF EUROPEAN TRENDS

被引：1
|
作者：
Rousseau, B. [1 ]
Poinas, A. [1 ]
Oliver, L. [1 ]
Collings, H. [1 ]
机构：
[1] Adelphi Values Ltd, Bollington, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1787
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP251
引用
收藏
页码：A695 / A696
页数：2
相关论文
共 50 条
  • [21] Trends in individual reimbursement of orphan drugs in Latvia in 2008-2011
    Logviss, K.
    Krievins, D.
    Purvina, S.
    4TH INTERNATIONAL INTERDISCIPLINARY SCIENTIFIC CONFERENCE SOCIETY, HEALTH, WELFARE, 2014, 10
  • [22] Pricing and reimbursement policy for new orphan drugs in South Korea: focused on patient accessibility and budget impact
    Lee, Jong Hyuk
    Yoo, Seung-Lai
    EXPERT OPINION ON ORPHAN DRUGS, 2022, 10 (01): : 23 - 28
  • [23] STATUS OF ORPHAN DRUGS AND REIMBURSEMENT RECOMMENDATIONS AND DECISIONS IN ANALYSED EUROPEAN COUNTRIES
    Kawalec, P.
    Malinowski, K.
    VALUE IN HEALTH, 2016, 19 (07) : A598 - A599
  • [24] ORPHAN VERSUS ULTRA-ORPHAN DRUGS PRICES IN ENGLAND
    Achour, L.
    Hanna, E.
    Borrisov, B.
    Toumi, M.
    VALUE IN HEALTH, 2018, 21 : S446 - S446
  • [25] Authorization and Reimbursement of Orphan Drugs in an International Comparison
    Roll, K.
    Stargardt, T.
    Schreyoegg, J.
    GESUNDHEITSWESEN, 2011, 73 (8-9) : 504 - 514
  • [26] AVAILABILITY AND REIMBURSEMENT OF ORPHAN DRUGS IN THE CZECH REPUBLIC
    Ornstova, E.
    Sebestianova, M.
    Paris, M.
    Mlcoch, T.
    Bartakova, J.
    Chadimova, K.
    Hajickova, B.
    Dolezal, T.
    VALUE IN HEALTH, 2018, 21 : S461 - S461
  • [27] Orphan Drug Pricing and Reimbursement Policies Lacking in EU
    不详
    PHARMACEUTICAL MEDICINE, 2018, 32 (04) : 297 - 298
  • [28] TITLE: ACCESS TO ORPHAN AND ULTRA-ORPHAN DRUGS IN CHINA
    Gambari, J.
    Yang, M.
    Chowdhury, C. A.
    Duttagupta, S.
    VALUE IN HEALTH, 2016, 19 (07) : A826 - A826
  • [29] HEALTH TECHNOLOGY ASSESSMENT, PRICE AND REIMBURSEMENT REVIEW FOR ORPHAN DRUGS IN ITALY
    Tavella, F.
    Korchagina, D.
    Rodrigues, J.
    Remuzat, C.
    VALUE IN HEALTH, 2014, 17 (07) : A540 - A540
  • [30] ELIGIBILITY OF ORPHAN DRUGS FOR PREFERENTIAL REIMBURSEMENT IN EGYPT
    Fasseeh, A. N.
    Elezbawy, B.
    Korra, N.
    Roushdy, M.
    Seyam, A.
    Hayek, N.
    Rahman, Abdel N.
    Abdelhamid, S.
    Fasseeh, N.
    Saad, A. S.
    Elagamy, A.
    Mahmoud, A.
    Sedrak, A. S.
    Elshazly, K.
    Eldebeiky, M.
    Talaat, M.
    Maher, N.
    Abdelaziz, R.
    Refaat, R.
    Akeel, S.
    Adel, R.
    Khalil, S.
    Abaza, S.
    Kalo, Z.
    VALUE IN HEALTH, 2022, 25 (12) : S265 - S265
12345